Verastem Oncology Partners With Genfleet Therapeutics For Three Oncology Discovery Programs For $11.5M To Genfleet For The First Program, With Potential Deal Size Across All Three Programs Up To $625.5M Excluding Royalties If Verastem Exercises Its Option
Portfolio Pulse from Benzinga Newsdesk
Verastem Oncology has partnered with Genfleet Therapeutics for three oncology discovery programs. The deal is worth $11.5M for the first program, with a potential total deal size of up to $625.5M excluding royalties if Verastem exercises its option. Verastem Oncology will have exclusive rights to obtain a license to each of the compounds after successful completion of pre-determined milestones in Phase 1 trials.
August 28, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verastem Oncology's partnership with Genfleet Therapeutics for three oncology discovery programs could potentially increase the company's value up to $625.5M excluding royalties.
The partnership with Genfleet Therapeutics provides Verastem Oncology with exclusive rights to obtain a license to each of the compounds after successful completion of pre-determined milestones in Phase 1 trials. This could potentially increase the company's value up to $625.5M excluding royalties if Verastem exercises its option.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100